Expertise in
1
conditions

Michael W. Ong

501 Smyth Road, 
Ottawa, ON, CA 
Expertise in
1
conditions
501 Smyth Road, 
Ottawa, ON, CA 

Overview

Michael Ong practices practicing medicine in Ottawa, Canada.

Ong is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Prostate Cancer, Eosinophilic Fasciitis, Urothelial Cancer, Melanoma, and Orchiectomy.

They are actively involved in clinical research, co-authoring 69 peer reviewed articles and participating in 2 clinical trials.

Locations

501 Smyth Road, Ottawa, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer
Enrollment Status: Unknown
Publish Date: December 06, 2017
Intervention Type: Drug
Study Drugs: Cabazitaxel, Abiraterone, Enzalutamide
Study Phase: Phase 2
View 1 Less Clinical Trial

69 Total Publications

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.
Journal: Future oncology (London, England)
Published: June 19, 2026

Frequently Asked Questions about Michael W. Ong

Is Michael W. Ong a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Michael W. Ong is classified as an Advanced expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael W. Ong participate in research or clinical trials?

Yes. Michael W. Ong has published 69 articles and abstracts on conditions like Prostate Cancer. You can view a list of Michael W. Ong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ong's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile